SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Stock data | 2024 | Change |
---|---|---|
Price | $6.74 | N/A |
Market Cap | $441.76M | N/A |
Shares Outstanding | 65.51M | N/A |
Employees | 65.00 | N/A |